GoAI
Get started
Cytokinetics, Incorporated logo

Cytokinetics, Incorporated

CYTK

NASDAQHealthcareBiotechnology

Open in GoAI

Regular session

$76.82

−$0.02 · -0.03%

Aug 24, 10:10 AM ET

CYTK company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

47

Fair Value

Momentum

66

Gaining

Sentiment

71

Bullish

Risk resilience

75

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Robert I. Blum
Listed since
Apr 26, 2004
Employees
673

Market position

Day range

Current $76.82

52-week range

Current $76.82

Open
$77.20
Previous close
$76.84
Volume
130.36K
0.06× average
Average volume
2.35M
Average daily volume
Market cap
9.56B USD
Beta
0.38
Market reference 1
50-day average
$79.5752
-3.46% below average
200-day average
$69.2038
+11.01% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
8.79B USD
P/E (TTM)
-10.65×
P/B (TTM)
-58.49×
P/S (TTM)
134.71×
EV / EBITDA
-11.34×
Earnings yield
-10.29%
Free cash flow yield
-7.01%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
84.97%
Operating margin
-992.98%
Net margin
-1259.87%
Return on equity
119.00%
Return on assets
-55.10%
Return on invested capital
-47.74%

Financial health

Debt / equity
-7.32×
Current ratio
4.53×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends796%-2035%-4865%-7696%Gross margin, FY2021: -127.09%Gross margin, FY2022: -154.59%Gross margin, FY2023: -4284.10%Gross margin, FY2024: -1737.22%Gross margin, FY2025: 88.50%Operating margin, FY2021: -264.54%Operating margin, FY2022: -342.75%Operating margin, FY2023: -6589.71%Operating margin, FY2024: -2902.72%Operating margin, FY2025: -695.44%Net margin, FY2021: -305.72%Net margin, FY2022: -411.21%Net margin, FY2023: -6988.63%Net margin, FY2024: -3191.11%Net margin, FY2025: -891.60%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -127.09%. Gross margin FY2022 -154.59%. Gross margin FY2023 -4284.10%. Gross margin FY2024 -1737.22%. Gross margin FY2025 88.50%. Operating margin FY2021 -264.54%. Operating margin FY2022 -342.75%. Operating margin FY2023 -6589.71%. Operating margin FY2024 -2902.72%. Operating margin FY2025 -695.44%. Net margin FY2021 -305.72%. Net margin FY2022 -411.21%. Net margin FY2023 -6988.63%. Net margin FY2024 -3191.11%. Net margin FY2025 -891.60%.

Income trends

Revenue

88.04M USD+376.56%

Operating income

−612.26M USD-14.17%

Net income

−784.96M USD-33.15%
Income trends across reported periods182.54M USD−169.27M USD−521.09M USD−872.91M USDRevenue, FY2021: 70.43M USDRevenue, FY2022: 94.59M USDRevenue, FY2023: 7.53M USDRevenue, FY2024: 18.47M USDRevenue, FY2025: 88.04M USDOperating income, FY2021: −186.31M USDOperating income, FY2022: −324.2M USDOperating income, FY2023: −496.21M USDOperating income, FY2024: −536.25M USDOperating income, FY2025: −612.26M USDNet income, FY2021: −215.31M USDNet income, FY2022: −388.96M USDNet income, FY2023: −526.24M USDNet income, FY2024: −589.53M USDNet income, FY2025: −784.96M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 70.43M USD. Revenue FY2022 94.59M USD. Revenue FY2023 7.53M USD. Revenue FY2024 18.47M USD. Revenue FY2025 88.04M USD. Operating income FY2021 −186.31M USD. Operating income FY2022 −324.2M USD. Operating income FY2023 −496.21M USD. Operating income FY2024 −536.25M USD. Operating income FY2025 −612.26M USD. Net income FY2021 −215.31M USD. Net income FY2022 −388.96M USD. Net income FY2023 −526.24M USD. Net income FY2024 −589.53M USD. Net income FY2025 −784.96M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue88.04M USD18.47M USD7.53M USD94.59M USD70.43M USD
Cost of goods sold10.13M USD339.41M USD330.12M USD240.81M USD159.94M USD
Gross profit77.91M USD−320.93M USD−322.59M USD−146.23M USD−89.51M USD
Research and development405.9M USD339.41M USD330.12M USD240.81M USD159.94M USD
Selling, general, and administrative284.27M USD215.31M USD173.61M USD177.98M USD96.8M USD
Operating expenses690.17M USD215.31M USD173.61M USD177.98M USD96.8M USD
Interest income48.42M USD51.53M USD27.63M USD11.34M USD331K USD
Interest expense103.87M USD86.51M USD57.67M USD51.16M USD29.33M USD
Depreciation and amortization9.69M USD9.53M USD11.89M USD8.4M USD9.64M USD
Operating income−612.26M USD−536.25M USD−496.21M USD−324.2M USD−186.31M USD
Net income−784.96M USD−589.53M USD−526.24M USD−388.96M USD−215.31M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 6 misses, 1 met estimate
Average EPS surprise
-10.51%
11 comparable reports
Latest EPS result
-1.5
Estimate -1.63 · Beat by 7.98%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-1.01-1.56-2.11-2.66Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26MetQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual -1.26, estimate -1.29, surprise +2.33%, Beat. Q2 2025, reported May 6, 2025: actual -1.36, estimate -1.41, surprise +3.55%, Beat. Q3 2025, reported Aug 7, 2025: actual -1.12, estimate -1.34, surprise +16.42%, Beat. Q4 2025, reported Nov 5, 2025: actual -2.55, estimate -1.59, surprise -60.38%, Miss. Q1 2026, reported Feb 24, 2026: actual -1.5, estimate -1.48, surprise -1.35%, Miss. Q2 2026, reported May 5, 2026: actual -1.67, estimate -1.67, surprise 0.00%, Met estimate. Q3 2026, reported Aug 6, 2026: actual -1.5, estimate -1.63, surprise +7.98%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate -1.45, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates71.98M48.44M24.89M1.34MQ1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 16.93M USD, estimate 14.26M USD, surprise +18.69%, Beat. Q2 2025, reported May 6, 2025: actual 1.58M USD, estimate 2.79M USD, surprise -43.36%, Miss. Q3 2025, reported Aug 7, 2025: actual 66.77M USD, estimate 2.07M USD, surprise +3131.07%, Beat. Q4 2025, reported Nov 5, 2025: actual 1.94M USD, estimate 6.05M USD, surprise -68.00%, Miss. Q1 2026, reported Feb 24, 2026: actual 17.76M USD, estimate 6.93M USD, surprise +156.34%, Beat. Q2 2026, reported May 5, 2026: actual 19.36M USD, estimate 8.52M USD, surprise +127.21%, Beat. Q3 2026, reported Aug 6, 2026: actual 28.62M USD, estimate 17.59M USD, surprise +62.75%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 39.77M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

35 ratings
Strong buy00%
Buy3497%
Hold13%
Sell00%
Strong sell00%

Recent analyst actions

12 institutions

CYTK news

fool.com

Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700

The transaction involved the disposal of 7,500 shares. The disposition resulted in a 2% reduction in the insider's total equity holdings.

Read source
globenewswire.com

Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026

Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy

Read source
zacks.com

Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock?

Myqorzo's early launch momentum and global expansion could boost Cytokinetics, while pipeline progress may widen its growth opportunity.

Read source
globenewswire.com

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 14, 2026 it granted stock options to purchase an aggregate of 27,565 shares of…

Read source
zacks.com

CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong

CYTK tops Q2 revenue estimates as Myqorzo gains traction, but higher launch costs and the absence of milestone payments weigh on results.

Read source
seekingalpha.com

Cytokinetics, Incorporated (CYTK) Q2 2026 Earnings Call Transcript

Cytokinetics, Incorporated (CYTK) Q2 2026 Earnings Call Transcript

Read source

CYTK peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding CYTK

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core S&P Mid-Cap ETF logoiShares Core S&P Mid-Cap ETFIJH
Market value
356.3M
Weight
0.28%
AUM
125.92B USD
Expense ratio
0.05%
Price / 1D
$76.355-0.54%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
333.91M
Weight
0.01%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$376.8-0.38%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
257.16M
Weight
0.32%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$298.4-0.52%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
240.58M
Weight
0.13%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$303.44-0.43%
Vanguard Morningstar Small-Cap Growth ETF logoVanguard Morningstar Small-Cap Growth ETFVBK
Market value
139.3M
Weight
0.31%
AUM
43.8B USD
Expense ratio
0.05%
Price / 1D
$354.29-1.22%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
120.56M
Weight
0.13%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$243.62-0.78%
State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
120.06M
Weight
1.05%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$162.38-2.02%
T. Rowe Price Capital Appreciation Equity ETF logoT. Rowe Price Capital Appreciation Equity ETFTCAF
Market value
93.81M
Weight
1.14%
AUM
8.27B USD
Expense ratio
0.31%
Price / 1D
$42.305-0.37%

Continue in GoAI

Research CYTK

research.disclaimer